A following research (Cost Analysis of Treating Neonatal Hypoglycaemia with Dextrose Gel), published in The Journal of Pediatrics (Glasgow, Harding, & Edlin, 2018) supports the use of dextrose gel on economic grounds:
In the primary analysis, treating neonatal hypoglycaemia using dextrose gel had an overall cost of NZ$ 6.863,81 and standard care (placebo) cost NZ$ 8.178,25; a saving of NZ$ 1.314,44 (approx. € 790,-) per infant treated. Sensitivity analyses showed that dextrose gel remained cost saving with wide variations in dextrose gel costs, neonatal intensive care unit costs, caesarean delivery rates, and costs of monitoring.
Use of buccal dextrose gel reduces hospital costs for management of neonatal hypoglycaemia. Because it is also non-invasive, well tolerated, safe, and associated with improved breastfeeding, buccal dextrose gel should be routinely used for initial treatment of neonatal hypoglycaemia.
Following these scientific studies, BioProNeo has been requested by the neonatology department of Erasmus Sophia Children’s Hospital in Rotterdam, The Netherlands, to supply a dextrose gel easily applicable in neonates and dosable per kg bodyweight. Other dextrose gels have been used by the hospital, but there is a need for a more practical, sterile and easily applicable gel for which the dose could be adjusted per kg bodyweight. BioProNeo has specifically developed DexProNeo for this purpose.
DexProNeo is a 40% dextrose gel without preservatives in 6 ml sterile syringes and the desired dose can easily be applied.
- Ready to administer;
- Time saving;
- Sterile, no preservatives;
- Syringe for buccal dosing only: connection to IV-tubings NOT possible